[{"id":"783c2f96-ba30-478f-862b-676b7775d699","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451488","created_at":"2021-01-18T11:45:13.513Z","updated_at":"2024-07-02T16:36:50.247Z","phase":"Phase 4","brief_title":"Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma","source_id_and_acronym":"NCT02451488","lead_sponsor":"Mayo Clinic","biomarkers":" CSF2 • GATA3","pipe":" | ","alterations":" CSF2 expression","tags":["CSF2 • GATA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CSF2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/04/2016","primary_completion_date":" 11/04/2016","study_txt":" Completion: 11/04/2016","study_completion_date":" 11/04/2016","last_update_posted":"2020-02-10"}]